Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  buparlisib
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, NCT01695473
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, CBKM120ZUS32T, ISS22810064, NCT01623349
PI3K Inhibitor BKM120 and Rituximab in Treating Patients with Relapsed or Refractory B-Cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-13027, NCI-2014-00110, 2013C0156, NCT02049541
Buparlisib, Cisplatin, and Radiation Therapy in Treating Patients with Stage III/IV Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
Buparlisib and Ibrutinib in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, or Diffuse Large B Cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-009, NCI-2016-00760, NCT02756247
Sonidegib and Buparlisib in Treating Patients with Advanced or Metastatic Basal Cell Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0020, NCI-2014-02200, 5136, NCT02303041
Start Over